 |
|
|
|
 |
|
|
|
|
|
|
Department
|
Hematology/Oncology
|
|
Hospital Title
|
Associated in Medicine
|
|
Academic Title
|
Associate Professor of Medicine
|
|
Phone
|
617-632-5642
|
|
Fax
|
617-582-8218
|
|
Email
|
Lisa Diller
|
|
Location
|
Dana-Farber Cancer Institute
44 Binney Street
Boston MA 02115
|
 |
 |
|
|
|
|
|
|
|
The focus of our research is in two major areas: the treatment of patients with
solid tumors -- notably neuroblastoma and Wilms' tumor -- and the study of
survivors of childhood cancer.
In treating patients with neuroblastoma, our approach has been to intensify
therapy using high-dose therapy in tandem with stem cell rescue. In addition, we
are studying new approaches to treatment of minimal residual neuroblastoma with
new agents, including studies of anti-angiogenic agents, demethylating agents
and immunomodulatory approaches. Studies of survivors of neuroblastoma are
underway. We are participants in the NANT (New Agents in Neuroblastoma Therapy)
consortium.
In research on medical late effects, we have been studying young adult patients
with a history of cancer treatment, hoping to delineate the morbidity of a
variety of therapies and to introduce screening and prevention in this group of
patients. An early mammography trial after chest irradiation has been completed,
showing that women who were treated with chest radiation are at significant risk
of breast cancer and that mammography detects early tumors in this cohort. A
prevention trial using tamoxifen for these women is in analysis.
We are active participants in the largest childhood cancer survivor cohort
study, the Childhood Cancer Survivor Study, involving 24 centers and over 17,000
survivors. We have completed an analysis of breast cancers in that cohort, and
we are studying risk factors for secondary sarcomas. Interventional studies using that cohort are underway, including a web-based smoking cessation intervention, an analysis of breast cancer screening behaviours, and a planned study of renal disease screening.
|
|
|
|
|
|
Lisa Diller received her MD from the University of California, San Diego, School of Medicine. She completed an internship, residency, and fellowship at Children's Hospital Boston.
|
|
|
|
|
- Diller L, Medeiros-Nancarrow C, Shaffer K, Matulonis U, Mauch P, Neuberg D, Tarbell NJ, Litman H, Garber J. Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. Journal of Clinical Oncology 2002; 20: 2085-2091.
- Nichols KE, Heath JA, Friedman D, Biegel JA, Ganguly A, Mauch P, Diller LR. The TP53, BRCA1 and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms. J Clin Oncol 2003;21:4505-9.
- Recklitis C, O'Leary T, Diller L. Utility of routine psychological screening in the childhood cancer survivor clinic. J Clin Oncol 2003;21:787-92.
- George RE, Lipshultz SE, Lipsitz SR, Colan SD, Diller L. Association between congenital cardiovascular malformations and neuroblastoma. Journal of Pediatrics. 2004;144(4):444-8.
- Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, Greenbaum N, Mauch P, Lipschultz SE. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. Journal of Clinical Oncology 2004;22(15):3139-3148.
- Kenney LB, Yasui Y, Inskip PD, Hammond S, Neglia JP, Mertens AC, Meadows AT, Friedman D, Robison LL, Diller L. Breast cancer after childhood cancer: A report from the Childhood Cancer Survivors Study. Annals of Internal Medicine. 2004:141(8):590-7.
- Carpentieri SC, Diller LR. Neuropsychological resiliency after treatment for advanced stage neuroblastoma. Bone Marrow Transplant. 2005;35(11):1117-22.
- Ng AK, Li S, Recklitis C, Neuberg D, Chakrabarti S, Silver B, Diller L. A comparison between long-term survivors of Hodgkin's disease and their siblings on fatigue level and factors predicting for increased fatigue. Ann Oncol. 2005.
- George R, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger R, Pulsipher M, Grupp S, Diller L. High Risk neuroblastoma treated with tandem autologous peripheral blood stem cell-supported transplant: long-term survival update. J Clin Oncol. 2006 Jun 20;24(18);2891-6.
|
|
|
|
|
|
|
|
|
|
|
